Ocugen, Inc.
- OCGN
- NASDAQ
- Biotechnology
- Gene Therapy (Ocular)
- Ophthalmology Treatments
$0.79
Today +0.90%Quote Oct 19, 2026, 08:00 PM UTC
−25.73%over the last month
Max drawdown −28.4%From 1-month high −27.8%3 months −39.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Ocugen
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
116
Market value
$267.0M
Quote Oct 19
Floor
$0.75
5.3% below price
Resistance
$0.85
7.6% above price
Price vs analyst targets
6 analysts
Lowest target
$3.50Highest target
$6.00
$3.50Highest target
$6.00
- Price $0.79
- Average target $5.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 535% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about OCGNPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free